Senior Software Engineer, Formation Bio
Emerging Products, Artificial Intelligence/Large Language Model
$175-230k
Plus equity
End-to-end medical trial solutions
Open for applications
End-to-end medical trial solutions
101-200 employees
Open for applications
$175-230k
Plus equity
101-200 employees
Company mission
To bring new treatments to patients faster and more efficiently.
Role
Who you are
- Bachelor’s or Master’s degree in Computer Science, Engineering, or a related field, or equivalent experience
- Minimum of 5 years of experience in software development, with a demonstrated ability to thrive in ambiguous and rapidly-changing environments, with a proven track record of contributing significantly to the successful launch and scaling of new and innovative products, especially in a 0-1 setting
- Exceptional collaboration and communication skills to effectively engage and work along stakeholders from diverse disciplines and varying levels of technical expertise. Ideally, adept at translating complex technical concepts into clear, actionable insights for all audiences
- Experience with AI technologies, particularly in LLMs and machine learning
- Familiarity with cloud infrastructure (e.g., AWS, Azure, GCP) and the full end-to-end process of modern software deployment (e.g., containerization, CI/CD)
- Experience in the pharmaceutical or biotech industry is a plus, but not required
What the job involves
- Lead the design, development, and deployment of software solutions that leverage AI and LLM technologies in the strategic drug development process
- Collaborate with cross-functional teams, including product managers and domain experts, to discover, build, and iterate on innovative features and products
- Ensure the scalability, security, and performance of our software systems
- Rapidly develop and iterate on proofs-of-concept to test new ideas and hypotheses to efficiently validate and evolve our software solutions in alignment with strategic objectives in drug development
- Stay abreast of emerging trends and advancements in AI, LLMs, and software development to continually enhance our product offerings
- Act as an internal evangelist for use of AI and LLMs, providing expert guidance and insights to other teams within the organization
Our take
Clinical drug trials are lengthy and expensive, delaying the supply of vital new drugs to patients and costing lives. For Formation Bio, this is an efficiency issue - one which it hopes to solve with its end-to-end automation solution.
According to the company, its approach has teams running medical trials twice as fast and at half the cost. It's worked so well, in fact, that Formation Bio is looking to take drug development in-house.
Now a Unicorn, the company has secured heavyweights like Pfizer, Sanofi, Novartis and 23andMe as partners. Precisely how it will fare in the Big Pharma ecosystem remains to be seen, but the promise of cheaper drugs and faster innovation is certainly causing a stir in a market that has historically been resistant to both.
Kirsty
Company Specialist
Insights
Company
Funding (last 2 of 3 rounds)
Jun 2024
$372m
SERIES D
Sep 2021
$156m
SERIES C
Total funding: $530.3m
Company values
- Think in first principles
- Be a scientist
- Deliver care
- Champion the mission
Company HQ
Midtown South, New York, NY
Articles
Leadership
Benjamine Liu
(CEO)Worked as a computational biologist at various Neurology departments, following a D.Phil in computational Biology and Psychiatry at Oxford. They are also an Advisor at Harvard Business School.
Share this job
View 10 more jobs at Formation Bio